Increased levels of obesity are driving an epidemic of non-alcoholic fatty liver disease. Understanding, diagnosing and treating this progressive condition are now priorities.
Calories not alcohol
An advanced stage of non-alcoholic fatty liver disease (NAFLD) was first described in 1980, confirming that liver disease characterized by an accumulation of fat can develop in people who do not consume excess alcohol1. Associated with obesity and type 2 diabetes, NAFLD is set to become the most common cause of serious liver disease in many nations.
Age, gender and genetics all contribute to a person’s risk of developing NAFLD and NASH. But the main risk factors are obesity and diabetes, as well as other features of metabolic syndrome, including high blood pressure and insulin resistance.
The link between obesity, its complications and NAFLD is strong.
Diabetes and insulin resistance
In healthy people, insulin inhibits the breakdown and release of fat by fat cells (adipocytes).
In people with insulin resistance, fat is secreted into the bloodstream, from where it is taken up by hepatocytes.
To determine the extent of NAFLD and associated fibrosis, and to monitor patients’ responses to treatment — without using an invasive liver biopsy — biomarker discovery and advances in imaging technology are needed.
In the blood
Although current blood tests for liver disease can help to assess the severity of NAFLD, researchers are seeking new biomarkers with concentrations that reliably correlate with disease activity.
Diagnostic tools that use ultrasound technology can help to assess the health of the liver, but the fine resolution and sensitivity of such techniques needs improvement.
The cornerstones of NAFLD treatment are weight loss and increased amounts of exercise, but maintaining these lifestyle changes can be hard. NASH is now considered to be a serious condition that requires the development of targeted drugs. As a result, hundreds of trials of potential treatment strategies are under way.
This article is part of the Fatty liver disease Outline, an editorially independent supplement produced with the financial support of a third party. About this content.
1. Ludwig, J., Viggiano, T. R., McGill, D. B. & Oh, B. J. Mayo Clin. Proc. 55, 434–438 (1980).
2. Younossi, Z. M. et al. Hepatology 64, 73–84 (2016).
3. Rinella, M. E. JAMA 313, 2263–2273 (2015).
4. Younossi, Z. M. et al. Clin. Gastroenterol. Hepatol. 9, 524–530 (2011).
5. Lazo, M. et al. Am. J. Epidemiol. 178, 38–45 (2013).
Related links in Nature Research
PrimeView: Nonalcoholic fatty liver disease
Primer: Nonalcoholic fatty liver disease
Lipid droplets and liver disease: from basic biology to clinical implications
Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease
Nonalcoholic steatohepatitis (NASH) drugs market
Nature Outline: Critical limb ischaemia
Rights and permissions
About this article
Cite this article
Drew, L. Fighting the fatty liver. Nature 550, S102–S103 (2017). https://doi.org/10.1038/550S102a
This article is cited by
Hepatic subcellular distribution of squalene changes according to the experimental setting
Journal of Physiology and Biochemistry (2018)